Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Delcath Systems, Inc./ 8-K

Current Report · Items 2.02, 9.01 · 8-K

Delcath Systems, Inc.

DCTHNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On August 6, 2026, Delcath Systems, Inc. (“Delcath”) issued a press release announcing financial results and business highlights for the quarter ended June 30, 2026 (the “Press Release”). A copy of the press release is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.…

Filed Aug 6, 2026Accepted Aug 6, 2026, 8:10 AM EDTCIK 872912Accession 0001628280-26-053902
View company →Permanent SEC source ↗
Share

Company context

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System (HDS) for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

Current securities

DCTHNASDAQ · EQUITY · Current

Recent company filings

  1. S-8 filingAug 14, 2026
  2. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAug 14, 2026
  3. 10-Q filingAug 6, 2026
  4. SCHEDULE 13G filingJul 28, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security HoldersMay 14, 2026

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition. On August 6, 2026, Delcath Systems, Inc. (“Delcath”) issued a press release announcing financial results and business highlights for the quarter ended June 30, 2026 (the “Press Release”). A copy of the press release is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference. The information contained in this Current Report on Form 8-K, including the Press Release, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the Press Release shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission by Delcath whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Filed exhibits (1)
EX-99.1 (by filename) dcth-q22026erex991.htm

EX-99.1 2 dcth-q22026erex991.htm EX-99.1 Document Exhibit 99.1 Delcath Systems Reports Second Quarter 2026 Results and Business Highlights Increases 2026 Revenue Guidance to a Range of $104M to $108M Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY - August 6, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Results • Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 ◦ HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 ◦ CHEMOSAT® revenue of $2.0 million, compared to $1.7 million in the second quarter of 2025 • Gross margins of 90%, compared to 86% in the second quarter of 2025 • Net income of $2.7 million for both second quarters in 2026 and 2025 • Non-GAAP adjusted EBITDA of $7.6 million, compared to $9.8 million in the second quarter of 2025 • Cash provided by operations of $5.7 million in the quarter; compared to $7.3 million in the second …

Open exhibit ↗